 |
 |
 |
 |
 |
 |
About Cellerant |
|
Cellerant Therapeutics is a biotechnology company with a portfolio of products based on the regulation of the hematopoietic (blood-forming) system. The company focuses on curative therapies for seriously ill patients. Cellerant is developing a novel, cell-based medicine (Myeloid Progenitors / CLT-008) as a treatment for chemotherapy- and radiation-induced neutropenia as well as for Acute Radiation Syndrome. And we are applying our expertise in hematopoietic ontogeny to identify novel drug targets and therapeutic antibodies aimed at cancer stem cells. |
Cellerant in the News | ||
 |
|
April 23, 2007 Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice with Transplant of Purified Donor Blood Stem Cells |
|
|
December 12, 2006 Cellerant Therapeutics Presents Positive Preclinical Data on Purified Blood-Forming Stem Cells at ASH |
|
||
|
|
November 1, 2005 Cellerant Therapeutics Appoints Ramkumar Mandalam as Vice President of Pharmaceutical Operations |
|
||
|
|
September 22, 2005 Cellerant Adds $9 Million to Series B Round for a Total of $25 Million |
|
||
|
|
|
|
Cellerant is Hiring |
||
|
|
Join our team |
|
||
|
|
|